What Types of Cancers can CyberKnife Radiosurgery System Treat?

The CyberKnife SuperDimension System : The most advance Lung/Thorsac capabilities available, through the cutting edge tool called the SuperDimension Bronchus System. Using the SuperDimension system, with the CyberKnife VSI imaging system, all lung abnormalities that show up on X-rays and CT-scans are within reach of a bronchoscope.

Therefore, this new minimally invasive approach to biopsy replaces the need for high-risk invasive procedures, such as intrathoracic needle biopsy and open surgery. This advanced technology of SuperDimension sets the stage for an earlier diagnosis, and an earlier diagnosis improve success rates in treatment.

The CyberKnife VSI’s Synchrony System provides unprecedented accuracy that also extends to the treatment of tumors which move with the body as an individual breathes in respiration, due to the CyberKnife VSI’s technology that “learns” and matches patient’s respiratory patterns, and accounts for them, allowing the precise dose to always be targeted at the tumor, making CyberKnife VSI highly effective for kidney and renal-cell cancer and tumors. CyberKnife VSI differs from radiation therapy, which irradiates both normal and cancerous tissues.

CyberKnife VSI delivers an ablative dose to the tumor with submillimeter accuracy and minimal exposure of normal tissue. As a result, we can treat inoperable patients, shrink tumors for less radical resections, destroy radioresistant tumors and treat patients previously treated with radiation. In addition, patients experience short, painless treatments with far fewer side effects, limited (if any) downtime and an immediate return to activities.

CyberKnife VSI differs from radiation therapy, which irradiates both normal and cancerous tissues. CyberKnife VSI delivers an ablative dose to the tumor with submillimeter accuracy and minimal exposure of normal tissue. As a result, we can treat inoperable patients, shrink tumors for less radical resections, destroy radioresistant tumors and treat patients previously treated with radiation. In addition, patients experience short, painless treatments with far fewer side effects, limited (if any) downtime and an immediate return to activities.

CyberKnife VSI prostate radiosurgery effectively addresses shortcomings of other treatments for early stage prostate cancer. It is less invasive, with faster recovery than radical prostatectomy, vastly shorter in duration and with sharper treatment margins compared with external beam radiotherapy, potentially less urologically traumatic and obstructive than permanent source brachytherapy, and less invasive than HDR brachytherapy. Post a Query

With radiotherapy, it is very challenging to deliver a potentially curative radiation dose to the pancreatic tumor volume, due to its typical close approximation to the stomach, duodenum, small intestine, large intestine, liver, kidneys and spinal cord, and the CyberKnife VSI offers the most precise technology to accurately deliver radiotherapy.

The CyberKnife VSI Synchrony respiratory tracking system locks onto implanted gold fiducial markers and correlates their position with the respiratory cycle as determined by optical tracking, to track the targeted lesion with 1.5 mm accuracy throughout the entire breathing cycle, allowing a much smaller applied margin compared with other radiation delivery systems. This gives CyberKnife VSI the distinction of being the only device that currently brings radiosurgical precision to a respiration-induced moving target such as the pancreas.

Many nonsurgical approaches have also been applied to unresectable hepatobiliary lesions, including radiofrequency ablation, cryoablation, chemoembolization, direct hepatic chemotherapeutic infusion, and systemic chemotherapy. Radiotherapy has also been used to treat hepatobiliary lesions. Traditional forms of radiotherapy have had a limited role in the management of hepatobiliary lesions, largely due to the fact that the liver parenchyma itself is very sensitive to radiation injury, particularly if a large volume of hepatic tissue is irradiated to a dose larger than 30Gy.

Contemporary high dose conformal radiotherapy has yielded more meaningful and durable clinical responses in patients with hepatobiliary neoplasms, and the CyberKnife VSI offer the best option to these types of liver aliments.

The advantages of CyberKnife VSI treatment for breast cancers include fewer technical limitations, more convenient treatment schedules, better accuracy and a lower risk of toxicity due to smaller volumes of healthy breast and surrounding tissue receiving radiation. CyberKnife VSI differs from radiation therapy, which irradiates both normal and cancerous tissues. CyberKnife VSI delivers an ablative dose to the tumor with submillimeter accuracy and minimal exposure of normal tissue.

As a result, we can treat inoperable patients, shrink tumors for less radical resections, destroy radioresistant tumors and treat patients previously treated with radiation. In addition, patients experience short, painless treatments with far fewer side effects, limited (if any) downtime and an immediate return to activities. Refer a Patient